Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 516
- Registration Number
- NCT01659567
- Locations
- 🇬🇪
Hepatology Clinic Hepa, Tbilisi, Georgia
🇬🇪Ltd Mrcheveli, Tbilisi, Georgia
🇬🇪Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia
PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT01659970
A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT01655381
A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT01654211
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Drug: CHOP
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 572
- Registration Number
- NCT01649856
- Locations
- 🇳🇱
Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed, Rotterdam, Netherlands
🇳🇱Isala Klinieken, Locatie Sophia; Inwendige Geneeskunde, Zwolle, Netherlands
🇮🇪Galway Uni Hospital; Oncology Dept, Galway, Ireland
A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 183
- Registration Number
- NCT01649817
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT01649804
A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT01645969
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (MONACO)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT01643863
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 415
- Registration Number
- NCT01641939
- Locations
- 🇬🇹
Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, Guatemala
🇲🇽Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
🇲🇽Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico